POVIDONE-IODINE BETADINE

Size: px
Start display at page:

Download "POVIDONE-IODINE BETADINE"

Transcription

1 POVIDONE-IODINE BETADINE NAME OF PRODUCT BETADINE 10% OINTMENT Read this leaflet carefully before you start using BETADINE ointment. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. DESCRIPTION OF PRODUCT POVIDONE-IODINE (BETADINE ) ointment is a reddish brown, smooth, homogenous ointment. It is available in 5 & 15 g aluminum tube. 1. WHAT IS BETADINE OINTMENT? POVIDONE-IODINE (BETADINE ) ointment is a topical agent active against organisms commonly encountered in skin and wound infections. It contains 10% povidone-iodine equivalent to 1% available iodine. The active ingredient povidone-iodine substantially retains the broad spectrum germicidal activity of iodine against the commonly encountered organisms in skin and wound infections, without the undesirable features or disadvantages of iodine. POVIDONE-IODINE (BETADINE ) ointment is decisively microbicidal against all 4 major classes of pathogens: bacteria (both Gram-positive and Gram-negative, as well as antibiotic-resistant strains) fungi, viruses and protozoa. The foremost documented broad spectrum topical microbicidal power of POVIDONE-IODINE (BETADINE ) ointment is active even in the presence of blood, pus and serum and the germicidal activity is more prolonged than that of iodine tincture. POVIDONE-IODINE (BETADINE ) ointment is in a water-soluble base and is not greasy or sticky. It permits bandaging of treated area, is virtually non-irritating to skin and mucosa and does not block air from reaching site of application. It easily washes off from skin and natural fabrics. POVIDONE-IODINE (BETADINE ) ointment does not interfere with granulation or skin grafting in burns. 2. STRENGTH OF BETADINE OINTMENT Each g contains 100 mg POVIDONE-IODINE (BETADINE ) equivalent to 10 mg available iodine 3. WHAT IS BETADINE OINTMENT USED FOR? POVIDONE-IODINE (BETADINE ) ointment is an ideal topical agent for the treatment of common skin infections; prevention of infection in minor burns, lacerations, cuts and abrasions; and for infection control during insertion and care of urinary catheters, circumcision, suture removal and dressing changes.

2 POVIDONE-IODINE (BETADINE ) ointment may be used for degerming care of stasis ulcers, decubitus ulcers and the umbilical area. It can be used also for degerming during use of intravenous devices in blood transfusions, hyperalimentation, cutdowns, CVP catheterization and in other procedures where degerming is needed. 4. HOW MUCH AND HOW OFTEN SHOULD YOU USE BETADINE OINTMENT? Use POVIDONE-IODINE (BETADINE ) Ointment as prescribed by your doctor. Clean and dry the affected skin. Apply POVIDONE-IODINE (BETADINE ) ointment liberally and cover with a dressing or bandage. POVIDONE-IODINE (BETADINE ) ointment may be used as often as required. If you have any further questions on the use of POVIDONE-IODINE (BETADINE ) ointment, ask your doctor or pharmacist. 5. WHEN SHOULD YOU NOT USE BETADINE OINTMENT? POVIDONE-IODINE (BETADINE ) ointment should not be used: If you are allergic to iodine or povidone If you have an overactive thyroid gland (hyperthyroidism) or any thyroid diseases If you are on lithium therapy Before and after a specific medical treatment involving the use of radioactive iodine If you feel you have experienced an allergic reaction, stop using POVIDONE-IODINE (BETADINE ) ointment and inform your doctor or pharmacist immediately. 6. SIDE EFFECTS All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects. The side effects listed below may not include all of the side effects reported. For more information about any other possible risks associated with POVIDONE-IODINE (BETADINE ) ointment, please consult your doctor or pharmacist. Please note that the side effects related to the use of POVIDONE-IODINE (BETADINE ) ointment occur rarely. Rarely, hypersensitive/allergic skin reaction may occur, which can appear in the form of: itchiness redness small blisters Very rarely, acute generalized allergic reactions have been reported with drop in blood pressure difficulty in breathing swelling of the skin and mucosa

3 If you notice any side effects, please consult your doctor or pharmacist. The long term use of the product, not in accordance with the usage instructions mentioned under section 4, may lead to possible absorption of iodine into the body. This may lead to overactive thyroid gland function if you have a history of thyroid problems, rapid heartbeat (tachycardia) and restlessness imbalance of electrolytes abnormal blood concentration (osmolarity) abnormal kidney function (renal impairment) 7. WHAT OTHER MEDICINE OR FOOD SHOULD BE AVOIDED WHILE USING BETADINE OINTMENT? Do not apply other medications to the same affected areas you treat with POVIDONE- IODINE (BETADINE ) ointment, unless your doctor has told you so. It is not likely that other drugs you take orally or inject will have an effect on externally applied POVIDONE-IODINE (BETADINE ) ointment. The concomitant use of other externally applied wound healing medicines /preparations may alter the effect of POVIDONE-IODINE (BETADINE ) ointment or both. Products containing enzymatic component, alkali, mercury, silver, hydrogen peroxide, tannic acid and taurolidine may interact with povidone-iodine and should not be used concomitantly. Povidone-iodine products when used concomitantly or immediately after application of octenidine containing antiseptics in the same or adjacent sites may lead to transient dark discolorations in the areas involved. Due to the oxidative effect of povidone-iodine preparations various diagnostic agents can show false-positive lab results (e.g., tests with toluidine or gum guaiac for the determination of hemoglobin or glucose in the stool or the urine). Absorption of iodine from povidone-iodine may interfere with thyroid function tests. Do not start a new treatment medication without telling your doctor. For more information about any other possible risks associated with POVIDONE-IODINE (BETADINE ) ointment, please consult your doctor or pharmacist. 8. WHAT SHOULD YOU DO IF YOU MISS A DOSE? Follow the usage instructions mentioned in section 4. If you miss a treatment use it as soon as you remember. For more information please consult your doctor or pharmacist. 9. HOW SHOULD YOU KEEP BETADINE OINTMENT? Do not use POVIDONE-IODINE (BETADINE ) ointment after the expiry date indicated on the tube and carton. Store at temperatures not exceeding 30 C. 10. SIGNS & SYMPTOMS OF OVERDOSE In the unlikely event you experience any of the following symptoms: stomach pain, unable to pass urine, loss of appetite, weakness, nausea and vomiting, coughing up

4 blood, excessive sweating, difficulty in breathing, metabolic acidosis, anxiety and pale skin, immediately consult your doctor. Treatment is symptomatic and supportive. 11. WHAT TO DO WHEN YOU HAVE USED MORE THAN THE RECOMMENDED DOSAGE? Please consult your doctor or pharmacist. 12. CARE THAT SHOULD BE TAKEN WHEN USING BETADINE OINTMENT In pre-operative preparation, avoid pooling beneath the patient. Prolonged exposure to wet solution may cause irritation or rarely, severe skin reactions. Chemical burns of skin due to pooling may occur. In instances of skin irritation, contact dermatitis or hypersensitivity, discontinue use. Do not heat POVIDONE-IODINE (BETADINE ) ointment prior to use. Avoid getting POVIDONE-IODINE (BETADINE ) ointment in your eyes. Avoid solutions containing a detergent if treating open wounds with povidone-iodine. POVIDONE-IODINE (BETADINE ) ointment is intended FOR EXTERNAL USE ONLY. Not for use on extensive body areas and should not be used over a long period of time unless strictly indicated. Patients with goiter, thyroid nodules or other non-acute thyroid diseases are at risk of developing thyroid hyperfunction (hyperthyroidism) from the administration of large amounts of iodine. In this patient population, povidone-iodine should not be applied for an extended period of time and to large areas of the skin unless strictly indicated. Even after the end of the treatment one should look for the early symptoms of possible hyperthyroidism and if necessary the thyroid function should be monitored. It should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma. Newborns and small infants are at increased risk of developing hypothyroidism from the administration of large amounts of iodine. Because of the permeable nature of the skin and their increased sensitivity to iodine, the use of povidone-iodine should be kept to the absolute minimum in newborns and small infants. A check of their thyroid function (e.g. T 4 levels and TSH levels) may be necessary. Avoid use in patients with renal impairment. If symptoms persist, consult your doctor. Pregnancy and Lactation During pregnancy and lactation, POVIDONE-IODINE (BETADINE ) ointment should only be used if strictly prescribed by the doctor and its use should be kept to the absolute minimum. Seek medical advice from your doctor or pharmacist. 13. WHEN SHOULD YOU CONSULT YOUR DOCTOR? In case of allergic symptoms, stop treatment and consult your doctor.

5 Call your doctor if your symptoms do not improve or if they get worse. Also call your doctor if your symptoms had cleared up but reappeared again. Manufactured for: By: Mundipharma Distribution GmbH Interphil Laboratories, Inc. (Philippine Branch) Canlubang Industrial Estate, 29/F Robinsons Equitable Tower, Bo. Pittland, Cabuyao, Laguna #4 ADB Ave. cor. Poveda St., Ortigas Center, Pasig City, Philippines 1605 Under license by: Mundipharma B.V. / The Netherlands : BETADINE is a Registered Trademark. This leaflet was last revised on December 10, 2015 (CCDS v.4 16 November 2015). PH-BET-0566-V3-1215

PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone

PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You

More information

PATIENT INFORMATION LEAFLET. Naseptin Nasal Cream chlorhexidine dihydrochloride and neomycin sulfate

PATIENT INFORMATION LEAFLET. Naseptin Nasal Cream chlorhexidine dihydrochloride and neomycin sulfate PATIENT INFORMATION LEAFLET Naseptin Nasal Cream chlorhexidine dihydrochloride and neomycin sulfate Read all of this leaflet carefully before you start using this medicine Keep this leaflet. You may need

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg/5 ml Oral Suspension fusidic acid Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

PHENYLEPHRINE. Please read this leaflet and the label of the medicine you purchased, carefully before you start using Phenylephrine.

PHENYLEPHRINE. Please read this leaflet and the label of the medicine you purchased, carefully before you start using Phenylephrine. What is in this leaflet PHENYLEPHRINE New Zealand Consumer Medicine Information The medicine you have purchased contains Phenylephrine. This leaflet is intended to provide information on the active ingredient

More information

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET PATIENT INFORMATION LEAFLET PROSTATIN (OCTREOTIDE ACETATE INJECTION 10mcg, 50mcg) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again.

More information

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET PPM Code: E1981 PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S2 PROPRIETARY NAME DOSAGE FORM: film coated tablets Read all of this leaflet carefully because it contains important information for you.

More information

FASTUM 2.5% gel PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT FASTUM GEL IS AND WHAT IT IS USED FOR

FASTUM 2.5% gel PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT FASTUM GEL IS AND WHAT IT IS USED FOR PACKAGE LEAFLET: INFORMATION FOR THE USER FASTUM 2.5% gel KETOPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines the

More information

AUGMENTIN is also used to prevent infection from major surgery.

AUGMENTIN is also used to prevent infection from major surgery. Injection Potassium clavulanate/amoxicillin sodium equivalent to 100 mg clavulanic acid/500 mg amoxicillin Potassium clavulanate/amoxicillin sodium equivalent to 200 mg clavulanic acid/1 g amoxicillin

More information

Consumer Medicine Information TOPICIL. Please read this leaflet carefully before you start using Topicil Capsules.

Consumer Medicine Information TOPICIL. Please read this leaflet carefully before you start using Topicil Capsules. Clindamycin hydrochloride Capsules 150 mg What is in this leaflet Consumer Medicine Information TOPICIL Please read this leaflet carefully before you start using Topicil Capsules. This leaflet answers

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg Tablets sodium fusidate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

More information

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime Package leaflet: Information for the user Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Bicillin L-A Benzathine benzylpenicillin tetrahydrate

Bicillin L-A Benzathine benzylpenicillin tetrahydrate Bicillin L-A Benzathine benzylpenicillin tetrahydrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Bicillin L- A. It does not contain all the available

More information

PATIENT INFORMATION LEAFLET. Nasoxyl nasal spray solution 1 mg/ml

PATIENT INFORMATION LEAFLET. Nasoxyl nasal spray solution 1 mg/ml PATIENT INFORMATION LEAFLET Nasoxyl nasal spray solution 1 mg/ml Read all of this leaflet carefully, because it contains important information for you. This medicine is available without prescription.

More information

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased

More information

PHOLCODINE. Please follow the instructions on the packaging of the medicine you purchased and in this leaflet before you start using pholcodine.

PHOLCODINE. Please follow the instructions on the packaging of the medicine you purchased and in this leaflet before you start using pholcodine. PHOLCODINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains pholcodine. This leaflet is intended to provide information on the active ingredient

More information

How Entecavir GH Works

How Entecavir GH Works entecavir monohydrate tablets ENTECAVIR GH Tablets Consumer Medicine Information What is in this leaflet Read this leaflet carefully before taking. This leaflet answers some common questions about. It

More information

Package leaflet: Information for the patient. Megalac Almasilate 1 g/10 ml suspension. Active substance: almasilate

Package leaflet: Information for the patient. Megalac Almasilate 1 g/10 ml suspension. Active substance: almasilate Package leaflet: Information for the patient Megalac Almasilate 1 g/10 ml suspension Active substance: almasilate Read all of this leaflet carefully before you start taking this medicine because it contains

More information

PATIENT INFORMATION LEAFLET CARZIN XL

PATIENT INFORMATION LEAFLET CARZIN XL SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: 4 mg film coated tablets. Read all of this leaflet carefully before you start taking. Keep this leaflet. You may need to read it

More information

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

If you have any concerns about taking this medicine, ask your doctor or pharmacist. CHAMPIX Varenicline tartrate What is in this leaflet This leaflet answers some common questions about CHAMPIX. It does not contain all the available information. It does not take the place of talking to

More information

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet

More information

PATIENT INFORMATION LEAFLET PEPLOC RANGE

PATIENT INFORMATION LEAFLET PEPLOC RANGE Scheduling Status: S4 Proprietary name, Strength and Pharmaceutical Form: Peploc 20 mg tablets Peploc 40 mg tablets Read all of this leaflet carefully before using PEPLOC 20 mg or 40 mg Keep this leaflet.

More information

DIXARIT 25 mcg Tablets Clonidine Hydrochloride

DIXARIT 25 mcg Tablets Clonidine Hydrochloride New Zealand Consumer Medicine Information DIXARIT 25 mcg Tablets Clonidine Hydrochloride What is in this leaflet This leaflet answers some common questions about DIXARIT tablets. It does not contain all

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER SALAGEN 5 mg film-coated tablets Pilocarpine hydrochloride Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may

More information

Dulcolax Tablets and Dulcolax Suppositories Bisacodyl

Dulcolax Tablets and Dulcolax Suppositories Bisacodyl Consumer Medicine Information Tablets and Suppositories Bisacodyl What is in this leaflet 1. What is used for 2. Before you use a) When you must not use b) Before you start to use c) Pregnancy d) Breastfeeding

More information

Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam

Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

SPASMEX FORTE 5mg tablets

SPASMEX FORTE 5mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER SPASMEX FORTE 5mg tablets TROSPIUM This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

Ceclor CD cefaclor monohydrate sustained release tablets

Ceclor CD cefaclor monohydrate sustained release tablets Ceclor CD cefaclor monohydrate sustained release tablets Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Ceclor CD. It does not contain all

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion Read this carefully before you start

More information

SUCRALFATE ISELPIN 1 g Tablet

SUCRALFATE ISELPIN 1 g Tablet 1.0 PHARMACOLOGIC CATEGORY CYTOPROTECTOR 2.0 DESCRIPTION SUCRALFATE ISELPIN 1 g Tablet Sucralfate is a white, amorphous powder which is soluble in strong acids and in alkalis but practically insoluble

More information

PATIENT INFORMATION LEAFLET. Nu-Seals 75 aspirin (acetylsalicylic acid)

PATIENT INFORMATION LEAFLET. Nu-Seals 75 aspirin (acetylsalicylic acid) PATIENT INFORMATION LEAFLET Nu-Seals 75 aspirin (acetylsalicylic acid) Read all of this leaflet carefully before you start taking this medicine Keep this leaflet. You may need to read it again. If you

More information

1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER

1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER Fusidic acid 20 mg/g cream Page 1 of 6 1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER AffusineAffusine 20 mg/g cream Fusidic Acid Read all of this leaflet carefully before you start using this medicine

More information

NEXIUM INTRAVENOUS esomeprazole sodium

NEXIUM INTRAVENOUS esomeprazole sodium NEXIUM INTRAVENOUS esomeprazole sodium Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about NEXIUM Intravenous (IV). It does not contain

More information

BISOLVON Chesty Forte.

BISOLVON Chesty Forte. New Zealand Consumer Medicine Information BISOLVON Chesty Forte Tablets 8 mg Bromhexine hydrochloride What is in this leaflet This leaflet answers some common questions about BISOLVON Chesty Forte. It

More information

Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium)

Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium) Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium) Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet

More information

It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. Serc betahistine dihydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Serc. It does not contain all the available information. It does

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate) PACKAGE LEAFLET: INFORMATION FOR THE USER DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate) Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need

More information

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET FERIFER-40 Oral Solution, 40 mg/5 ml For oral use. PATIENT INFORMATION LEAFLET Active substance(s): Each one spoon solution (5 ml) contains 40 mg of iron (as iron III polymaltose complex). Excipient(s):

More information

FLUIMUKAN PLUS 600 mg effervescent tablets

FLUIMUKAN PLUS 600 mg effervescent tablets PACKAGE LEAFLET: INFORMATION FOR THE USER FLUIMUKAN PLUS 600 mg effervescent tablets Acetylcysteine This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for

More information

Package leaflet: Information for the patient. Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone)

Package leaflet: Information for the patient. Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone) PACKAGE LEAFLET Package leaflet: Information for the patient Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone) Read all of this leaflet carefully before you start using this medicine because

More information

PATIENT INFORMATION LEAFLET DYNARB RANGE

PATIENT INFORMATION LEAFLET DYNARB RANGE SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNARB 75 mg tablets DYNARB 150 mg tablets DYNARB 300 mg tablets Read all of this leaflet carefully before you start taking DYNARB.

More information

PATIENT INFORMATION LEAFLET. Calcichew* 500 mg Chewable Tablets calcium carbonate

PATIENT INFORMATION LEAFLET. Calcichew* 500 mg Chewable Tablets calcium carbonate PATIENT INFORMATION LEAFLET Calcichew* 500 mg Chewable Tablets calcium carbonate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

More information

Patient Information Leaflet

Patient Information Leaflet Patient Information Leaflet Ibuprofen 5% w/w Gel Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any further questions

More information

REDERGIN 1.5 mg tablets; 4.5 mg tablets; 1 mg/ml oral solution

REDERGIN 1.5 mg tablets; 4.5 mg tablets; 1 mg/ml oral solution PACKAGE LEAFLET: INFORMATION FOR THE USER REDERGIN 1.5 mg tablets; 4.5 mg tablets; 1 mg/ml oral solution ERGOLOID MESYLATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information

More information

PHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate

PHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate CONSUMER MEDICINE INFORMATION PHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate What is in this leaflet This leaflet answers some common questions

More information

PATIENT INFORMATION LEAFLET AMLOC RANGE

PATIENT INFORMATION LEAFLET AMLOC RANGE SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it

More information

Glucophage XR is contra-indicated during breast-feeding.

Glucophage XR is contra-indicated during breast-feeding. Name GLUCOPHAGE XR 1000 mg Prolonged release tablets Active ingredient Metformin hydrochloride Composition Each Glucophage XR 1000 mg prolonged release tablet contains as active ingredient 1000 mg metformin

More information

Patient Information MICARDIS HCT (my-car-dis HCT) (telmisartan and hydrochlorothiazide) Tablets

Patient Information MICARDIS HCT (my-car-dis HCT) (telmisartan and hydrochlorothiazide) Tablets Patient Information MICARDIS HCT (my-car-dis HCT) (telmisartan and hydrochlorothiazide) Tablets Read this Patient Information before you start taking MICARDIS HCT tablets and each time you get a refill.

More information

DESCRIPTION Locacorten-Vioform ear drops are a practically odourless clear, yellowish to brownish-yellow solution. Excipients: Macrogol 300

DESCRIPTION Locacorten-Vioform ear drops are a practically odourless clear, yellowish to brownish-yellow solution. Excipients: Macrogol 300 PRODUCT INFORMATION LOCACORTEN -VIOFORM Ear Drops NAME OF THE MEDICINE Flumethasone pivalate Chemical formula: C 27 H 36 F 2 O 6 (6α, 9-Difluouro-11β,17,21-trihydroxy-16α-methyl-pregna- 1,4-diene-3,20-dione

More information

Ca-C 1000 Calvive 1000 mg mg mg effervescent tablets

Ca-C 1000 Calvive 1000 mg mg mg effervescent tablets PACKAGE LEAFLET: INFORMATION FOR THE USER Ca-C 1000 Calvive 1000 mg + 327 mg + 1000 mg effervescent tablets CALCIUM LACTATE GLUCONATE, CALCIUM CARBONATE, ASCORBIC ACID (VITAMIN C) This leaflet is a copy

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER RENNIE DUAL ACTION TABLETS. Calcium carbonate, Magnesium carbonate, Alginic acid Chewable tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER RENNIE DUAL ACTION TABLETS. Calcium carbonate, Magnesium carbonate, Alginic acid Chewable tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RENNIE DUAL ACTION TABLETS Calcium carbonate, Magnesium carbonate, Alginic acid Chewable tablets Read all of this leaflet carefully because it contains important

More information

Package leaflet: Information for the user. Floxapen 250 mg & 500 mg Capsules. Flucloxacillin

Package leaflet: Information for the user. Floxapen 250 mg & 500 mg Capsules. Flucloxacillin Package leaflet: Information for the user Floxapen 250 mg & 500 mg Capsules Flucloxacillin Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration.

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration. Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration. Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion, 20 mg/ml Professed Standard Antineoplastic

More information

APOHEALTH Diarrhoea Relief PLUS

APOHEALTH Diarrhoea Relief PLUS APOHEALTH Diarrhoea Relief PLUS Chewable Tablets Contains the active ingredient Loperamide hydrochloride and Simethicone Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195

More information

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Neomycin Sulphate, Polymyxin B Sulfate and Bacitracin Zinc Powder

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Neomycin Sulphate, Polymyxin B Sulfate and Bacitracin Zinc Powder For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEOSPORIN ANTIBIOTIC POWDER Neomycin Sulphate, Polymyxin B Sulfate and Bacitracin Zinc Powder QUALITATIVE AND QUANTITATIVE

More information

Sensipar Cinacalcet hydrochloride

Sensipar Cinacalcet hydrochloride Sensipar Cinacalcet hydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Sensipar. It does not contain all the available information. It

More information

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride Package leaflet: Information for the patient / / 30 mg/5 ml syrup Ambroxol hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC.

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC. SCHEDULING STATUS: S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNAFLOC 250 (tablets) DYNAFLOC 500 (tablets) DYNAFLOC 750 (tablets) Read this entire leaflet carefully before you start taking

More information

Package leaflet: Information for the user. <product name> 3 mg/ml eye drops, solution. Ofloxacin

Package leaflet: Information for the user. <product name> 3 mg/ml eye drops, solution. Ofloxacin Package leaflet: Information for the user 3 mg/ml eye drops, solution Ofloxacin Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

More information

Hydrocortisyl Skin Cream 1% Hydrocortisone

Hydrocortisyl Skin Cream 1% Hydrocortisone PACKAGE LEAFLET: INFORMATION FOR THE USER Hydrocortisyl Skin Cream 1% Hydrocortisone Is this leaflet hard to see or read? Phone 01403 5600 for help Read all of this leaflet carefully before you start using

More information

PATIENT INFORMATION LEAFLET POLLENTYME S AND TABS

PATIENT INFORMATION LEAFLET POLLENTYME S AND TABS SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS (tablets) POLLENTYME S (syrup) Read all of this leaflet carefully because it contains important information

More information

METHYLDOPA 250 mg Film-coated Tablets

METHYLDOPA 250 mg Film-coated Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER METHYLDOPA 250 mg Film-coated Tablets METHYLDOPA This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,

More information

MEDICATION GUIDE SUTENT

MEDICATION GUIDE SUTENT MEDICATION GUIDE SUTENT (su TENT) (sunitinib malate) capsules Read the Medication Guide that comes with SUTENT before you start taking it and each time you get a refill. There may be new information. This

More information

Package leaflet: Information for the user. Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium)

Package leaflet: Information for the user. Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium) Package leaflet: Information for the user Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium) Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

FAVISTAN 20 mg, tablets

FAVISTAN 20 mg, tablets PACKAGE LEAFLET: INFORMATION FOR THE USER FAVISTAN 20 mg, tablets TIAMAZOL This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

1. What Solpadol is and what it is used for

1. What Solpadol is and what it is used for PATIENT INFORMATION LEAFLET SOLPADOL 30mg/500mg CAPLETS Codeine Phosphate and Paracetamol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read

More information

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Triprim against the benefits he or she expects it will have.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Triprim against the benefits he or she expects it will have. Triprim Tablets Trimethoprim Tablets Consumer Medicine Information What is in this leaflet? The leaflet answers some common questions about Triprim tablets. It does not contain all the available information

More information

PRESCRIBING INFORMATION

PRESCRIBING INFORMATION PRESCRIBING INFORMATION Bacitracin USP (Bacitracin for Injection USP) For Topical or Intramuscular Use in Solution 50 000 IU Sterile Powder Pfizer Canada Inc Date of Preparation: 17,300 Trans-Canada Highway

More information

Flavamed Forte 30 mg/5 ml, oral solution

Flavamed Forte 30 mg/5 ml, oral solution PACKAGE LEAFLET: INFORMATION FOR THE USER Flavamed Forte 30 mg/5 ml, oral solution AMBROXOL HYDROCHLORIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen PACKAGE LEAFLET: INFORMATION FOR THE USER EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking Easofen Max Strength Tablets because it contains

More information

Before you are given Privigen

Before you are given Privigen Normal immunoglobulin (Human) 10% (100 g/l), intravenous injection. Consumer Medicine Information What is in this leaflet This leaflet contains answers to some common questions about. It does not contain

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xylonase 0.1% w/v Nasal Spray, Solution Xylometazoline hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xylonase 0.1% w/v Nasal Spray, Solution Xylometazoline hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Xylonase 0.1% w/v Nasal Spray, Solution Xylometazoline hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains

More information

2. What you need to know before you take DDAVP/Desmopressin Tablets

2. What you need to know before you take DDAVP/Desmopressin Tablets Package Leaflet: Information for the user DDAVP /Desmopressin 0.1mg Tablets Desmopressin Acetate Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

PATIENT INFORMATION LEAFLET TEXAMER

PATIENT INFORMATION LEAFLET TEXAMER SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: film-coated tablets Read all of this leaflet carefully because it contains important information for you. is available without a doctor s prescription,

More information

POLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS

POLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS PROPOSED FINAL PATIENT INFORMATION LEAFLET FOR POLLENTYME TABLETS & POLLENTYME S PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS

More information

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Kopen Sugar Free 125mg/5ml and 250mg/5ml Powder for Oral Solution Phenoxymethylpenicillin Read all of this leaflet carefully before you start taking this medicine

More information

Duro-Tuss Dry Cough Liquid plus Nasal Decongestant Pholcodine (fol-co-dean); Pseudoephedrine hydrochloride (sue-doe-eff-eh-drine hydro-klor-ide)

Duro-Tuss Dry Cough Liquid plus Nasal Decongestant Pholcodine (fol-co-dean); Pseudoephedrine hydrochloride (sue-doe-eff-eh-drine hydro-klor-ide) Duro-Tuss Dry Cough Liquid plus Nasal Decongestant Pholcodine (fol-co-dean); Pseudoephedrine hydrochloride (sue-doe-eff-eh-drine hydro-klor-ide) Consumer Medicine Information What is in this leaflet This

More information

PART III: PATIENT MEDICATION INFORMATION. CLINDAMYCINE-150 Pr. CLINDAMYCINE-300 (Clindamycin Hydrochloride Capsules USP) Clindamycin 150 mg and 300 mg

PART III: PATIENT MEDICATION INFORMATION. CLINDAMYCINE-150 Pr. CLINDAMYCINE-300 (Clindamycin Hydrochloride Capsules USP) Clindamycin 150 mg and 300 mg PART III: PATIENT MEDICATION INFORMATION Pr CLINDAMYCINE-150 Pr CLINDAMYCINE-300 (Clindamycin Hydrochloride Capsules USP) Clindamycin 150 mg and 300 mg Read this carefully before you start taking CLINDAMYCINE

More information

PATIENT INFORMATION LEAFLET CARVETREND RANGE

PATIENT INFORMATION LEAFLET CARVETREND RANGE SCHEDULING STATUS: S3 PATIENT INFORMATION LEAFLET PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: CARVETREND 6,25 mg tablet. CARVETREND 12,5 mg tablet. CARVETREND 25 mg tablet. Please read this leaflet

More information

NEOFEN 60 mg suppository

NEOFEN 60 mg suppository PACKAGE LEAFLET: INFORMATION FOR THE USER NEOFEN 60 mg suppository IBUPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

PATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate

PATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate PATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read

More information

Thyroid Gland. Patient Information

Thyroid Gland. Patient Information Thyroid Gland Patient Information Contact details for Endocrine and Thyroid Clinics Hawke s Bay Fallen Soldiers Memorial Hospital Villa 16 Phone: 06 8788109 ext 5891 Text: 0274 102 559 Email: endoclinic@hbdhb.govt.nz

More information

Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride

Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride Package leaflet: Information for the user Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride Read all of this leaflet carefully before using this medicine because it

More information

PRODUCT MONOGRAPH. Pr KYTRIL. granisetron hydrochloride tablets. 1 mg granisetron as hydrochloride. Manufacture Standard

PRODUCT MONOGRAPH. Pr KYTRIL. granisetron hydrochloride tablets. 1 mg granisetron as hydrochloride. Manufacture Standard PRODUCT MONOGRAPH Pr KYTRIL granisetron hydrochloride tablets 1 mg granisetron as hydrochloride Manufacture Standard Antiemetic (5-HT 3 receptor antagonist) Hoffmann-La Roche Limited Date of Revision:

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Emerade 150 micrograms solution for injection in pre-filled pen Emerade 300 micrograms solution for injection in pre-filled pen Emerade 500 micrograms solution

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Kaliumjodide G.L. 65 mg tabletten Potassium iodide

PACKAGE LEAFLET: INFORMATION FOR THE USER. Kaliumjodide G.L. 65 mg tabletten Potassium iodide PACKAGE LEAFLET: INFORMATION FOR THE USER Kaliumjodide G.L. 65 mg tabletten Potassium iodide Read all of this leaflet carefully because it contains important information for you. This medicine is available

More information

Irbenida H 150mg/12,5mg film-coated tablets

Irbenida H 150mg/12,5mg film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER Irbenida H 150mg/12,5mg film-coated tablets IRBESARTAN/HYDROCHLOROTHIAZIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information

More information

Dulcolax 5 mg, film-coated tablets

Dulcolax 5 mg, film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER Dulcolax 5 mg, film-coated tablets BISACODYL This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which

More information

Consumer Medicine Information PIMAFUCORT

Consumer Medicine Information PIMAFUCORT Consumer Medicine Information PIMAFUCORT 1% Hydrocortisone, 1% Natamycin and 0.35% Neomycin Cream and Ointment What is in this leaflet This leaflet answers some common questions about Pimafucort Cream

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la] READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start

More information

PATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:

PATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You

More information

Lovastatin tablets 20 and 40 mg PACKAGE LEAFLET

Lovastatin tablets 20 and 40 mg PACKAGE LEAFLET PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Lovastatin Mylan 20 mg Tablets Lovastatin Mylan 40 mg Tablets lovastatin Read all of this leaflet carefully before you start taking this medicine.

More information

Mycamine Micafungin (as sodium)

Mycamine Micafungin (as sodium) Mycamine Micafungin (as sodium) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Mycamine. It does not contain all the available information. It does

More information

Package leaflet: Information for the patient. Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin

Package leaflet: Information for the patient. Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin Package leaflet: Information for the patient Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin Read all of this leaflet carefully before you start taking this medicine because it contains

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Paracetamol 500 mg Effervescent Tablets Paracetamol

PACKAGE LEAFLET: INFORMATION FOR THE USER Paracetamol 500 mg Effervescent Tablets Paracetamol PACKAGE LEAFLET: INFORMATION FOR THE USER Paracetamol 500 mg Effervescent Tablets Paracetamol Read all of this leaflet carefully because it contains important information for you. This medicine is available

More information

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate Package leaflet: Information for the user 100 mg/ml concentrate for solution for infusion argatroban monohydrate Read all of this leaflet carefully before you start using this medicine because it contains

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. ANESDERM 25 mg/g + 25 mg/g Cream Lidocaine, Prilocaine

PACKAGE LEAFLET: INFORMATION FOR THE USER. ANESDERM 25 mg/g + 25 mg/g Cream Lidocaine, Prilocaine PACKAGE LEAFLET: INFORMATION FOR THE USER ANESDERM 25 mg/g + 25 mg/g Cream Lidocaine, Prilocaine Read all of this leaflet carefully before you start using this medicine because it contains important information

More information